Predictive Oncology Builds "Strategic Compute Reserve" to Power AI Drug Discovery with ATH Tokens

Predictive Oncology Inc. has completed two private investment in public equity (PIPE) transactions, raising a total of $343.5 million to advance its digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem. The funding, announced on October 7, 2025, includes $50.8 million in cash from the sale of 4.4 million shares of common stock at $11.6265 per share and $292.7 million in notional value from the issuance of pre-funded warrants for 14.9 million shares, exchanged for locked and unlocked ATH tokens. The proceeds will be allocated to acquiring additional ATH tokens in the open market and supporting general corporate operationsPredictive Oncology closes $343.5M funding rounds for ATH …^[1].

The initiative aligns with Predictive Oncology's AI-driven drug discovery mission, leveraging Aethir's decentralized GPU infrastructure to enhance computational capabilities. Aethir's network, spanning 435,000 GPU containers across 200+ locations, offers cost savings of 40–80% compared to traditional cloud providers like AWS and Google Cloud. ATH tokens serve as a medium for GPU rentals, staking, and ecosystem rewards, with the company's treasury strategy aiming to establish the "world's first Strategic Compute Reserve" by functioning as an operator on the Aethir platformPredictive Oncology Inc. Announces Closing of $343.5^[2].

The funding follows a 1-for-15 reverse stock split approved by shareholders on September 19, 2025, which became effective on September 30. Post-split adjustments reflect the current share and price data in the announcement. CEO Raymond Vennare emphasized the transaction's role in addressing the company's growing computational needs while creating long-term exposure to the digital asset sector. "This strategic collaboration will enhance Aethir's ability to provide foundational infrastructure for global AI and machine learning," he statedPredictive Oncology closes $343.5M funding rounds for ATH …^[1].

Shawn Matthews, former CEO of Cantor Fitzgerald and incoming board member, highlighted ATH's potential to democratize AI infrastructure. "ATH exemplifies the future growth of artificial intelligence," he noted, underscoring the token's utility in staking and GPU accessPredictive Oncology Inc. Announces Closing of $343.5^[2]. The company's digital asset treasury will also benefit from a flywheel model: for every ATH token purchased, the DCI Foundation grants an additional 20%, linking token value to real-world infrastructure demandPredictive Oncology Inc. Announces Private Placements of $344 …^[3].

Advisors to the transaction include DNA Holdings Venture, Inc. (strategic advisor and Cash PIPE investor), H.C. Wainwright & Co. (placement agent), and law firms DLA Piper and Sheppard Mullin. The funding is subject to shareholder approval for pre-funded warrant exercises, which will become exercisable following regulatory clearancesPredictive Oncology closes $343.5M funding rounds for ATH …^[1].

Predictive Oncology's AI platform, PEDAL, already predicts drug response in tumor samples with 92% accuracy, supported by a biobank of 150,000 tumor samples. The company's integration of ATH into its treasury strategy reflects a broader trend of AI firms adopting digital assets to optimize compute resources and reduce costsPredictive Oncology Inc. Announces Closing of $343.5^[2].